--- title: "The innovative drug sector shows slight signs of recovery. What innovative drug-related ETFs are under E Fund?" type: "News" locale: "en" url: "https://longbridge.com/en/news/282357960.md" description: "On April 10th, the innovative drug sector saw a slight rebound, with the Hang Seng SCHK Innovative Drug Index and the CSI Innovative Drugs Industry Index both rising by 0.5%. Against this backdrop, the E Fund Innovative Drug ETF (159316) recorded a net subscription scale of 17 million shares throughout the day. CMB International pointed out that the biopharmaceutical industry has become an emerging pillar industry, with policy dividends continuing to be released. Breakthroughs in AI pharmaceutical technology and cooperation in the overseas expansion of Chinese innovative drugs are forming a dual resonance, and the industry's fundamentals are expected to accelerate positively" datetime: "2026-04-10T13:24:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282357960.md) - [en](https://longbridge.com/en/news/282357960.md) - [zh-HK](https://longbridge.com/zh-HK/news/282357960.md) --- # The innovative drug sector shows slight signs of recovery. What innovative drug-related ETFs are under E Fund? On April 10th, the innovative drug sector experienced a slight rebound, with core indices strengthening simultaneously. By the close, the Hang Seng SCHK Innovative Drug Index and the CSI Innovative Drugs Industry Index both rose by 0.5%, indicating a marginal recovery in sector sentiment. Against this backdrop, the Hang Seng SCHK Innovative Drug ETF E Fund (159316, connecting funds A/C: 024328/024329) saw a counter-trend capital allocation, with a net subscription scale reaching 17 million shares throughout the day. Zhongyin International pointed out that the biopharmaceutical industry is positioned to become an emerging pillar industry, signaling that policy dividends across the entire chain will continue to be released. Breakthroughs in AI pharmaceutical technology and the explosive growth of Chinese innovative drugs going overseas are creating a dual resonance, with the industry's fundamentals expected to accelerate positively. Currently, domestic innovative drug collaborations going overseas have upgraded from single pipeline licensing to platform-level cooperation, and multinational pharmaceutical companies' recognition of China's pharmaceutical R&D capabilities is systematically increasing. For more details on the innovative drug-related ETFs under E Fund, see the chart below: Risk Warning: Funds carry risks; investment requires caution ### Related Stocks - [560900.CN](https://longbridge.com/en/quote/560900.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [516080.CN](https://longbridge.com/en/quote/516080.CN.md) - [159835.CN](https://longbridge.com/en/quote/159835.CN.md) ## Related News & Research - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [A city at the center of an AI data center frenzy just voted to ban them](https://longbridge.com/en/news/287107998.md) - [Congress should stop being 'obstructionists', says FM Nirmala Sitharaman](https://longbridge.com/en/news/286946357.md) - [13:32 ETWorld-First AI Humanoid Robot Debuts on Cherie Barber's Ground-breaking Australian Reno Show](https://longbridge.com/en/news/286949647.md)